US5693622A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
Assignee: Wisconsin Alumni Research Foundation
•
Filing: 1995-06-07
•
Granted: 1997-12-02
•
Expires: 2015-06-07
Abstract
Abstract The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.
Inventors
- 👤 Jon A. Wolff
- 👤 David J. Duke
- 👤 Philip L. Felgner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:50
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/87; A; A61; A61K; A61K48/00; B; B82; B82Y; B82Y5/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
68 words
A method of delivering a desired physiologically active protein, polypeptide or peptide to a mammal, comprising: injecting into the cardiac muscle of the mammal a non-infectious, non-integrating DNA sequence encoding said protein, polypeptide or peptide operably linked to a promoter, wherein said DNA sequence is free from association with transfection-facilitating proteins, viral particles, liposomal formulations,, charged lipids and calcium phosphate precipitating agents, whereby said DNA sequence is expressed.
Claim 2
Independent Claim
68 words
A method of delivering a desired physiologically active protein, polypeptide or peptide to a mammal, comprising: injecting into the cardiac muscle of the mammal a non-infectious, non-integrating DNA sequence encoding said protein, polypeptide or peptide operably linked to a promoter, wherein said DNA sequence is free from association with transfection-facilitating proteins, viral particles, liposomal formulations,, charged lipids and calcium phosphate precipitating agents, whereby said DNA sequence is expressed.
Claim 3
Dependent Claim
17 words
The method of claim 1, wherein said DNA sequence is further free from any transfection facilitating material.
Claim 4
Dependent Claim
17 words
The method of claim 1 wherein said protein, polypeptide or peptide is immunologically native to said host.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein said protein, polypeptide or peptide is immunologically foreign to said host.
Claim 6
Dependent Claim
28 words
The method of claim 4 wherein said method additionally comprises administering an immunosuppressive agent to said host to limit immune responses directed to said protein, polypeptide or peptide.
Claim 7
Dependent Claim
18 words
The method of claim 5 wherein said host is immunosuppressed prior to said injection of said DNA sequence.
Claim 8
Dependent Claim
18 words
The method of claim 5 wherein said host is immunosuppressed simultaneous with said injection of said DNA sequence.
Claim 9
Dependent Claim
12 words
The method of claim 5 wherein said immunosuppressive agent is administered intravenously.
Claim 10
Dependent Claim
14 words
The method of claim 5 wherein said immunosuppressive agent is administered to the heart.
Claim 11
Dependent Claim
13 words
The method of claim 1 wherein said promoter is a muscle specific promoter.
Claim 12
Dependent Claim
13 words
The method of claim 1 wherein said promoter is a cardiac specific promoter.
Claim 13
Dependent Claim
23 words
The method of claim 1 wherein said DNA sequence contains a sequence operatively coding for the secretion of said protein, polypeptide or peptide.
Claim 14
Dependent Claim
16 words
The method of claim 1 wherein the production of said protein, polypeptide or peptide is transitory.
Claim 15
Dependent Claim
14 words
The method of claim 1 wherein said protein, polypeptide or peptide is an enzyme.
Claim 16
Dependent Claim
14 words
The method of claim 1 wherein said protein, polypeptide or peptide is a hormone.
Claim 17
Dependent Claim
15 words
The method of claim 1 wherein said protein, polypeptide or peptide is a growth factor.
Claim 18
Dependent Claim
15 words
The method of claim 1 wherein said protein, polypeptide or peptide is a regulatory sequence.
Claim 19
Dependent Claim
14 words
The method of claim 1 wherein said protein, polypeptide or peptide is an immunoregulator.
Claim 20
Dependent Claim
12 words
The method of claim 1 wherein said DNA sequence is injected myocardially.
Claim 21
Dependent Claim
18 words
The method of claim 1 wherein said DNA sequence is injected into the ventricular wall of the heart.
Claim 22
Dependent Claim
17 words
The method of claim 1 wherein said DNA sequence is injected in combination with a chelating agent.
Claim 23
Dependent Claim
11 words
The method of claim 21 wherein said chelating agent is EDTA.
Claim 24
Independent Claim
76 words
A method of delivering firefly luceriferase to the interior of a cardiac muscle cell of a rat, comprising injecting into heart of said rat a DNA plasmid constructed of sequence encoding said firefly luceriferase operably linked to a RSV promoter in an amount sufficient for said firefly luceriferase to be detected inside said cardiac muscle cell, wherein said plasmid is free from association with transfection-facilitating viral capsid proteins, liposomes, cationic lipids, and calcium phosphate precipitating agents.
Claim 25
Independent Claim
76 words
A method of delivering firefly luceriferase to the interior of a cardiac muscle cell of a rat, comprising injecting into heart of said rat a DNA plasmid constructed of sequence encoding said firefly luceriferase operably linked to a RSV promoter in an amount sufficient for said firefly luceriferase to be detected inside said cardiac muscle cell, wherein said plasmid is free from association with transfection-facilitating viral capsid proteins, liposomes, cationic lipids, and calcium phosphate precipitating agents.
References Cited (Backward Citations)
US3931397A
Cited
US4224404A
Cited
US4394448A
Cited
US4689320A
Cited
EP0188574A1
Cited
US4699880A
Cited
US4945050A
Cited
EP0187702A1
Cited
US4806523A
Cited
US4806463A
Cited
US4704692A
Cited
WO1988005077A1
Cited
JPS6447381A
Cited
WO1989009271A1
Cited
WO1990001543A1
Cited
WO1991002805A2
Cited
JPH03102682A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-01 | 2001-06-02 | 2001-12-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-01 | 2005-06-02 | 2005-12-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-01 | 2009-06-02 | 2009-12-02 | $7700.00 | Window Closed / Lapsed |